知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

114 records (took 0.037 seconds)

    Methods and Compositions For Treating Disease
    62.
    发明申请
    Methods and Compositions For Treating Disease 审中-公开

    公开(公告)号：US20170191027A1

    公开(公告)日：2017-07-06

    申请号：US15417598

    申请日：2017-01-27

    Applicant: Intrexon Corportion

    Inventor： Thomas D. REED ,  Robert P. BEECH

    IPC: C12N5/00 ,  C12N5/0789

    CPC classification number: C12N5/0093 ,  A61K38/45 ,  A61K48/00 ,  C12N5/0647 ,  C12N2501/724 ,  C12N2510/00 ,  C12Y204/02036

    Abstract: The present invention relates to methods and compositions for treating a subject comprising destroying diseased cells in the subject. The methods comprise obtaining a population of cells from a subject and determining the activity of at least one disease marker gene within the population of the obtained cells. A polynucleotide molecule that encodes a polypeptide that is lethal to the cells is then introduced into the cells, where the expression of the lethal polypeptide is controlled by the promoter of at least one of the disease marker genes previously identified. After introduction of the polynucleotide, the cells are treated with conditions to induce expression of the lethal polypeptide to destroy the cells that are expressing the disease marker gene(s). After destruction of the diseased cells, the remaining live cells, which did not express the lethal polypeptide to an extent necessary to kill the cells, are separated from the dead cells, and the live cells are restored to the subject.

    COMPOSITIONS AND METHODS FOR TREATING CANCER
    65.
    发明申请
    COMPOSITIONS AND METHODS FOR TREATING CANCER 审中-公开

    公开(公告)号：US20170128360A1

    公开(公告)日：2017-05-11

    申请号：US15319386

    申请日：2015-06-16

    Applicant: Purdue Research Foundation

    Inventor： Ruben Claudio Aguilar

    IPC: A61K9/00 ,  A61K38/16 ,  A61K38/45 ,  A61K38/18

    CPC classification number: A61K9/0034 ,  A61K9/1271 ,  A61K38/164 ,  A61K38/1808 ,  A61K38/45 ,  C07K14/485 ,  C07K2319/55 ,  C12Y204/02036

    Abstract: The invention generally relates to compositions and methods for treating cancer. In certain embodiments, the invention provides methods that involve treating a cancer in a patient in which cancerous cells overexpress epidermal growth factor receptor as compared to non-cancerous cells. The methods involve administering a first composition including anthrax protective antigen modified to bind an epidermal growth factor receptor of a cell, and administering a second composition including anthrax lethal factor N-terminus fused to a catalytic domain of Diphtheria Toxin A. Binding of anthrax lethal factor N-terminus to anthrax protective antigen results in internalization of Diphtheria Toxin A into the cancerous cell, which triggers apoptosis by inactivation of critical elongation factors.

    Modified forms of pseudomonas exotoxin A
    70.
    发明授权
    Modified forms of pseudomonas exotoxin A 有权
    假单胞菌外毒素A的修​​饰形式

    公开(公告)号：US09447387B2

    公开(公告)日：2016-09-20

    申请号：US14984006

    申请日：2015-12-30

    Applicant: Intrexon Corporation

    Inventor： Timothy David Jones ,  Francis Joseph Carr

    IPC: C12N9/10 ,  C07K16/28 ,  C07K14/21 ,  A61K39/00 ,  A61K39/02 ,  A61K38/00

    CPC classification number: C12N9/1077 ,  A61K38/00 ,  A61K39/00 ,  A61K39/02 ,  C07K14/21 ,  C07K16/2803 ,  C07K2317/622 ,  C12Y204/02036

    Abstract: Pseudomonas exotoxin A or “PE” is a 66kD, highly potent, cytotoxic protein secreted by the bacterium Pseudomonas aeruginosa. Various forms of PE have been coupled to other proteins, such as antibodies, to generate therapeutically useful cytotoxin conjugates that selectively target cells of a desired phenotype (such as tumor cells). In the present invention, peptides spanning the sequence of an approximately 38kD form of Pseudomonas exotoxin A protein were analyzed for the presence of immunogenic CD4+ T cell epitopes. Six immunogenic T cell epitopes were identified. Residues were identified within each epitope for introduction of targeted amino acid substitutions to reduce or prevent immunogenic T-cell responses in PE molecules which may be administered to a heterologous host.

    Abstract translation: 假单胞菌外毒素A或“PE”是由细菌绿脓假单胞菌分泌的66kD，高效的细胞毒性蛋白质。 已经将各种形式的PE偶联到其它蛋白质，例如抗体，以产生选择性靶向所需表型细胞（例如肿瘤细胞）的治疗上有用的细胞毒素缀合物。 在本发明中，分析跨越约38kD形式的假单胞菌外毒素A蛋白的序列的免疫原性CD4 + T细胞表位的存在。 鉴定了6种免疫原性T细胞表位。 在每个表位内鉴定出残基，用于引入靶向氨基酸取代，以减少或预防可能施用于异源宿主的PE分子中的免疫原性T细胞应答。

Patent Agency Ranking